Formycon Gets UK Nod For Eylea Biosimilar
Teva-Partnered Ahzantive Version Of Aflibercept Receives MHRA Approval
Formycon has celebrated receiving a UK approval for its Ahzantive biosimilar version of Eylea, setting up a launch from partner Teva – which has already seen success in the UK market with the partners’ Lucentis biosimilar, Ongavia.
